Clinical Trial Update: A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) [Phase 2, Phase 3]

View source ↗

Summary

A compassionate use protocol update for AMX0035 in ALS has completed Phase 2 and Phase 3 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• AMX0035 (sodium phenylbutyrate and tauroursodeoxycholic acid)

Snippet

Sponsor: Amylyx Pharmaceuticals Inc. | Conditions: Amyotrophic Lateral Sclerosis | Phase 2, Phase 3 | Status: COMPLETED